| Identification | Back Directory | [Name]
TAUROURSODEOXYCHOLIC ACID SODIUM SALT | [CAS]
35807-85-3 | [Synonyms]
TUDC
auroursodeoxycholate Sodium
SODIUM TAUROURSODEOXYCHOLATE
Tauroursodeoxycholate (Sodium)
Sodium Tauroursodeoxycholate (TUDC)
Sodium tauroursodesoxycholate, >=97%
TAUROURSODEOXYCHOLIC ACID SODIUM SALT
TAUROURSODEOXYCHOLIC ACID SODIUM SALTr
Tauroursodeoxycholic Acid SodiuM Salt (90%)
TAURO-URSODEOXYCHOLIC ACID, MONOSODIUM SALT
5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE-3ALPHA,7BETA-DIOL SODIUM SALT
5-BETA-CHOLANIC ACID-3-ALPHA, 7-BETA-DIOL N-(2-SULPHOETHYL)-AMIDE SODIUM SALT
3ALPHA,7BETA-DIHYDROXY-5BETA-CHOLAN-24-OIC ACID N-[2-SULFOETHYL]AMIDE SODIUM SALT
2-(3α,7β-Dihydroxy-24-oxo-5β-cholan-24-yl)amino-1-ethanesulfonic acid sodium salt
2-[(3α,7β-Dihydroxy-24-oxo-5β-cholane-24-yl)amino]-1-ethanesulfonic acid sodium salt
2-[[(3α,5β,7β)-3,7-Dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonic acid sodium salt
Ethanesulfonic acid,2-[[(3a,5b,7b)-3,7-dihydroxy-24-oxocholan-24-yl]amino]-, sodium salt (1:1)
sodium,2-[[(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C26H44NNaO6S | [MDL Number]
MFCD00065451 | [MOL File]
35807-85-3.mol | [Molecular Weight]
521.69 |
| Chemical Properties | Back Directory | [Melting point ]
173-175°C | [alpha ]
+40～+50°(D/20℃) | [storage temp. ]
-20°C Freezer | [solubility ]
DMSO (Slightly, Heated), Ethanol (Slightly, Sonicated), Methanol (Slightly) | [form ]
Solid | [color ]
Off-White to Pale Beige | [Water Solubility ]
water: 100mg/mL | [InChIKey]
WSSCRQYICWZEFG-SXXADWEANA-N | [SMILES]
C[C@]12CC[C@]3([H])[C@]4(CC[C@@H](O)C[C@@]4([H])C[C@H](O)[C@@]3([H])[C@]1([H])CC[C@]2([H])[C@H](C)CCC(=O)NCCS(O)(=O)=O)C.[NaH] |&1:1,4,6,9,12,15,17,19,23,25,r| |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. | [General Description]
Sodium tauroursodeoxycholate is a bile salt which is naturally present in the small bowel. | [in vivo]
The effects of Tauroursodeoxycholate (TUDCA) on proliferation and apoptosis of VSMCs in vivo are examined using immunohistochemistry. Tauroursodeoxycholate (10, 50, and 100 mg/kg) increases the caspase 3 activity of injured tissues in a dose-dependent manner, indicating that Tauroursodeoxycholate induces apoptosis of VSMCs in the neointima. Using the injured tissues, further examination and comparison of the phosphorylation level of ERK and MMP-9 expression is performed at 1 week after injury, compared with normal controls. Balloon injury increased both the phosphorylation of ERK and expression of MMP-9 in the tissues. Tauroursodeoxycholate (10, 50, and 100 mg/kg) inhibits phosphorylation of ERK and MMP-9 expression in a dose-dependent manner[1]. Tauroursodeoxycholate (TUDCA) is a hydrophilic bile acid. Tauroursodeoxycholate as a cytoprotective agent improves liver function and can prevent hepatocellular carcinoma by reducing ER stress and apoptosis. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3, caspase-12, C/EBP homologous protein, c-Jun N-terminal kinase (JNK), activating transcription factor 4 (ATF4), X-box binding protein (XBP), and eukaryotic initiation factor 2α (eIF2α) in Ang II induced ApoE-/- mice (p<0.05). Tauroursodeoxycholate reduces Angiotensin (Ang) II induced abdominal aortic aneurysm (AAA)? formation in ApoE-/- mice. Tauroursodeoxycholate is used at a dose of 0.5 g/kg/day in treating Ang II induced ApoE-/- mice (ER stress inhibitor group). Systolic blood pressure (141.3±5.6 mmHg vs 145.9±8.9 mmHg; p>0.05) and total cholesterol levels (663.6±88.7 mg/dL vs 655.7±65.4 mg/dL; p>0 .05) do not differ between the AAA model group and Tauroursodeoxycholate group. In addition, maximum aortic diameter is significantly smaller in those in Tauroursodeoxycholate group compared with those in the AAA model group (0.95±0.03 mm vs 1.79±0.04 mm; p<0.05). AAA lesion areas are also smaller in those in Tauroursodeoxycholate group than in those in the AAA model group (0.37±0.03 mm2 vs 1.51±0.06 mm2; p<0.05)[2]. | [IC 50]
ERK; Caspase-3; Caspase-12; Human Endogenous Metabolite |
|
|